Overactive bladder PGx.
Information for your prescriber. A focused CYP2D6 test for medications used to treat overactive bladder and urinary symptoms, including mirabegron and tamsulosin. One saliva sample, run in our CLIA-certified lab, with results your prescriber can refer back to.
- One sample, no blood draw
- Results in 3–7 business days
- Share with any prescriber
Panel
1 gene · CYP2D6
Sample
Saliva or cheek swab
Results
3–7 business days
Price
From $289
What we test
Panel medications.
See how your genes may affect your response to certain medications. Review your results with your prescriber.
Mirabegron, tamsulosin — CYP2D6
CYP2D6 metabolizer status changes how these medications are processed — poor metabolizers reach higher levels and may feel more side effects; ultra-rapid metabolizers may get less benefit.
Who this is for
The same dose can work differently in different people.
Side effects on current medication
Dizziness, dry mouth or other side effects may be a metabolism question, not a dose question.
No improvement on a standard dose
Rapid metabolizers can clear the medication before it does its job.
Other CYP2D6 medications
Antidepressants and many other drugs share CYP2D6 — one result informs both.
Is this test right for you?
You take or are starting medication for overactive bladder.
Your current medication caused dizziness or other side effects.
Symptoms have not improved on a standard dose.
You take other medications processed by CYP2D6.
Your urologist suggested genetic testing.
You want results you can keep for future prescriptions.
Answering yes to even one of these is a good reason to test before the next prescription change.
Before you order
Total price
From $289
One-time price, shown in full at checkout before you pay. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
A saliva or cheek-swab kit with instructions, a prepaid return label, the healthcare provider order, genetic testing in our lab and a gene-drug report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
Who reviews the results
A board-certified geneticist
Every report is reviewed and signed in our lab by a board-certified molecular geneticist before it is released.
The science
What the evidence says about getting tested.
Mirabegron and tamsulosin both pass through CYP2D6, one of medicine's most variable drug genes. Poor metabolizers accumulate roughly twice the mirabegron exposure — a difference large enough that the FDA label sets a daily cap for that group — while ultra-rapid metabolizers can clear the drug before it fully works. One gene explains side effects and non-response alike.
≈2×
higher mirabegron exposure in CYP2D6 poor metabolizers — the FDA label sets a daily dose cap for that group.
Source: FDA mirabegron labeling
≈7%
of people are CYP2D6 poor metabolizers, among the largest drug-metabolism groups in the population.
Source: CYP2D6 pharmacogenetics literature
1–5%
are CYP2D6 ultra-rapid metabolizers in European populations (higher in some African and Middle Eastern populations), clearing medication before it fully works.
Source: CYP2D6 pharmacogenetics literature
≈25%
of common medications are processed by CYP2D6, so one result informs many prescriptions beyond urology.
Source: Pharmacology reviews
How often should you test?
Test once — CYP2D6 genotype doesn't change. The highest-value moments are before starting mirabegron or tamsulosin, after side effects on a current medication, and whenever a standard dose has not delivered improvement.
References
- U.S. National Library of Medicine, DailyMed — mirabegron (Myrbetriq) prescribing information: CYP2D6 poor-metabolizer exposure and dose cap.
- U.S. National Library of Medicine, DailyMed — tamsulosin prescribing information: CYP2D6 metabolism and interactions.
- PubMed literature — CYP2D6 metabolizer phenotype frequencies across populations.
Population data
How common is each metabolizer type?
Published population frequencies for the cytochrome P450 enzymes read on this panel. Your report places you in one of these groups for each enzyme.
| Cytochrome | Poor metabolizer | Intermediate metabolizer | Normal metabolizer | Rapid or ultra-rapid metabolizer |
|---|---|---|---|---|
| CYP2D6 | 4–7% | 9–35% | 50–90% | 2–3% |
| CYP2C9 | 3% | 30% | 68% | N/A |
| CYP2C19 | 2–20% | 24–36% | 14–44% | 30% |
Population frequencies compiled from CPIC guidelines and FDA pharmacogenomic biomarker tables; frequencies vary by ancestry.
Questions people actually ask
Bring data to your next urology visit.
One sample, one flat price, a report your prescribers can refer back to.